Stay informed with the latest clinical trial results, guideline updates, and evidence-based insights in NMIBC intravesical therapy. Updated regularly to support clinical decision-making.
Johnson & Johnson's TAR-200 (erdafitinib intravesical system) achieved a 75.5% complete response rate in BCG-unresponsive CIS patients, significantly outperforming intravesical chemotherapy. The sustained 12-month CR rate was 53.2%, representing a potential paradigm shift in bladder-sparing therapy.
The 2025 AUA Annual Meeting featured significant updates to NMIBC guidelines, including refined definitions of BCG-unresponsive disease, expanded indications for novel agents, and new recommendations on en bloc resection techniques. Key changes include recognition of ERBT as a preferred technique when expertise is available.
The global BCG shortage continues to impact clinical practice. This article reviews evidence-based strategies including reduced-dose BCG (1/3 dose), alternative induction schedules, sequential gemcitabine/docetaxel as a substitute, and prioritization frameworks to allocate limited BCG supply to the highest-risk patients.
A comprehensive meta-analysis of 15 randomized controlled trials (n=2,847) demonstrates that en bloc resection of bladder tumours (ERBT) achieves significantly higher detrusor muscle sampling rates (96% vs. 72%), lower recurrence at 12 months (21% vs. 38%), and comparable complication rates versus conventional TURBT.
Updated 3-year data from the KEYNOTE-676 trial demonstrates that the combination of pembrolizumab with BCG achieves a 45% sustained complete response rate in BCG-unresponsive CIS patients, with a 72% bladder-intact event-free survival. The combination was well-tolerated with no new safety signals.
A multi-center registry study of 3,200 patients confirms that blue light cystoscopy (BLC) with hexaminolevulinate detects 40% more CIS lesions and 20% more papillary tumours compared to white light cystoscopy alone, leading to a 12% absolute reduction in recurrence at 12 months.
A comprehensive patient-friendly guide explaining the BCG instillation process, from preparation (fluid restriction, avoiding caffeine) through the procedure itself (catheter insertion, 2-hour retention) to post-treatment care (hydration, monitoring symptoms). Includes a printable checklist for each treatment session.
CG Oncology's cretostimogene grenadenorepvec (CG0070) achieved a 75.7% complete response rate at any time in BCG-unresponsive CIS patients in the BOND-003 Phase 3 trial, with a favorable safety profile. The oncolytic adenovirus-based therapy represents a promising new mechanism for intravesical treatment.